BH.IMMUN&BIO | EMMESSAR CHM | BH.IMMUN&BIO/ EMMESSAR CHM |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | 34.8 | - | View Chart |
P/BV | x | 1.5 | 3.0 | 50.0% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO EMMESSAR CHM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
EMMESSAR CHM Mar-23 |
BH.IMMUN&BIO/ EMMESSAR CHM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 47 | 109.3% | |
Low | Rs | 21 | 19 | 110.8% | |
Sales per share (Unadj.) | Rs | 10.3 | 2.0 | 506.9% | |
Earnings per share (Unadj.) | Rs | -3.9 | 1.0 | -382.3% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 1.2 | -318.9% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | 13.3 | 153.3% | |
Shares outstanding (eoy) | m | 43.18 | 5.00 | 863.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 16.2 | 21.7% | |
Avg P/E ratio | x | -9.4 | 32.7 | -28.7% | |
P/CF ratio (eoy) | x | -9.5 | 27.6 | -34.5% | |
Price / Book Value ratio | x | 1.8 | 2.5 | 71.6% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 165 | 948.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 8 | 1,809.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 10 | 4,377.7% | |
Other income | Rs m | 11 | 18 | 60.5% | |
Total revenues | Rs m | 457 | 28 | 1,648.7% | |
Gross profit | Rs m | -161 | -7 | 2,332.2% | |
Depreciation | Rs m | 2 | 1 | 212.8% | |
Interest | Rs m | 71 | 0 | 706,000.0% | |
Profit before tax | Rs m | -223 | 10 | -2,302.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 5 | -1,215.8% | |
Profit after tax | Rs m | -166 | 5 | -3,301.4% | |
Gross profit margin | % | -36.0 | -67.6 | 53.3% | |
Effective tax rate | % | 25.3 | 47.9 | 52.8% | |
Net profit margin | % | -37.3 | 49.4 | -75.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 61 | 588.6% | |
Current liabilities | Rs m | 940 | 6 | 16,527.6% | |
Net working cap to sales | % | -130.6 | 541.1 | -24.1% | |
Current ratio | x | 0.4 | 10.7 | 3.6% | |
Inventory Days | Days | 85 | 5 | 1,807.1% | |
Debtors Days | Days | 1,135 | 39 | 2,934.9% | |
Net fixed assets | Rs m | 1,262 | 20 | 6,281.2% | |
Share capital | Rs m | 432 | 50 | 864.3% | |
"Free" reserves | Rs m | 450 | 17 | 2,698.3% | |
Net worth | Rs m | 882 | 67 | 1,323.5% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 81 | 2,001.9% | |
Interest coverage | x | -2.2 | 968.0 | -0.2% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.1 | 218.7% | |
Return on assets | % | -5.9 | 6.2 | -94.7% | |
Return on equity | % | -18.9 | 7.6 | -249.5% | |
Return on capital | % | -17.2 | 14.5 | -118.7% | |
Exports to sales | % | 0 | 69.5 | 0.0% | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | 7 | 0.0% | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 7 | 0.0% | |
Fx outflow | Rs m | 65 | 0 | - | |
Net fx | Rs m | -65 | 7 | -911.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 4 | 2,896.8% | |
From Investments | Rs m | 5 | -5 | -84.6% | |
From Financial Activity | Rs m | -147 | NA | - | |
Net Cashflow | Rs m | -34 | -2 | 1,974.7% |
Indian Promoters | % | 59.3 | 59.5 | 99.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.2 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 40.5 | 100.7% | |
Shareholders | 35,313 | 7,146 | 494.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | EMMESSAR CHM | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -3.06% | 0.31% |
1-Month | -2.23% | 22.62% | 0.08% |
1-Year | 28.97% | 59.40% | 54.11% |
3-Year CAGR | -13.27% | 26.07% | 14.46% |
5-Year CAGR | 30.36% | 22.19% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the EMMESSAR CHM share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of EMMESSAR CHM the stake stands at 59.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of EMMESSAR CHM.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
EMMESSAR CHM paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of EMMESSAR CHM.
For a sector overview, read our pharmaceuticals sector report.
Indian share markets continued the momentum as the session progressed and ended higher.